The Leclaza plus Rybrevant combination achieved statistically significant overall survival (OS) results. Johnson & Johnson expects Leclaza plus Rybrevant to extend OS by more than a year compared to Tagrisso monotherapy. The positive OS outcome for the combination strengthens its potential to become the first-line standard of care for EGFR-positive NSCLC.

On the 7th, Johnson & Johnson announced top-line OS results from the Phase III MARIPOSA study, which evaluated the efficacy of the combination of Leclaza plus Rybrevant in patients with locally advanced or metastatic NSCLC.

Leclaza is a third-generation tyrosine kinase inhibitor (TKI) targeting exon 19, and exon 21 (L858R) in EGFR-posi